Clinical Trial Update: NeoAdapt 3: Novel Biomarkers in the Evaluation of Neonatal Circulatory Insufficiency in Babies Suffering From Hypoxic Ischemic Encephalopathy

View source ↗

Summary

The NeoAdapt 3 trial evaluating novel biomarkers for neonatal circulatory insufficiency in babies with hypoxic-ischemic encephalopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoxic-ischemic Encephalopathy

Snippet

Sponsor: Brighton and Sussex University Hospitals NHS Trust | Conditions: Circulatory Failure | Status: COMPLETED